Crotalus atrox disintegrin reduces hemorrhagic transformation by attenuating matrix metalloproteinase‐9 activity after middle cerebral artery occlusion in hyperglycemic male rats
- 22 September 2018
- journal article
- conference paper
- Published by Wiley in Journal of Neuroscience Research
- Vol. 98 (1) , 191-200
Abstract
Hemorrhagic transformation after ischemic stroke is an independent predictor for poor outcome and is characterized by blood vessel rupture leading to brain edema. To date, no therapies for preventing hemorrhagic transformation exist. Disintegrins from the venom of Crotalus atrox have targets within the coagulation cascade, including receptors on platelets. We hypothesized that disintegrins from C. atrox venom can attenuate hemorrhagic transformation by preventing activation of matrix metalloproteinase after middle cerebral artery occlusion (MCAO) in hyperglycemic rats. We subjected 48 male Sprague‐Dawley rats weighing 240–260 g to MCAO and hyperglycemia to induce hemorrhagic transformation of the infarction. At reperfusion, we administered either saline (vehicle), whole C. atrox venom (two doses were used), or fractionated C. atrox venom (HPLC Fraction 2). Rats were euthanized 24 hr post‐ictus for measurement of infarction and hemoglobin volume. Reversed‐phase HPLC was performed to fractionate the whole venom and peaks were combined to form Fraction 2, which contained the disintegrin Crotatroxin. Fraction 2 protected against hemorrhagic transformation after MCAO, and attenuated activation of matrix metalloproteinase‐9. Administering matrix metalloproteinase antagonists prevented the protection by Fraction 2. The results of this study indicate that disintegrins found in C. atrox venom may have therapeutic potential for reducing hemorrhagic transformation after ischemic stroke. Moreover, the RP‐HPLC fractions retained sufficient protein activity to suggest that gentler and less efficient orthogonal chromatographic methods may be unnecessary to isolate proteins and explore their function.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01 NS084921)
This publication has 33 references indexed in Scilit:
- Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic StrokeFrontiers in Neurology, 2013
- Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusionNeuroscience, 2012
- Neurovascular Injury in Acute Hyperglycemia and Diabetes: a Comparative Analysis in Experimental StrokeTranslational Stroke Research, 2011
- S tem Cell T herapies as an E merging P aradigm in S troke (STEPS)Stroke, 2009
- Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in RatJournal of Cerebral Blood Flow & Metabolism, 2007
- Hyperglycemia in Acute StrokeStroke, 2004
- Diagnostic Uses of Snake VenomPathophysiology of Haemostasis and Thrombosis, 2001
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999
- Early Appearance of Activated Matrix Metalloproteinase-9 after Focal Cerebral Ischemia in Mice: A Possible Role in Blood—Brain Barrier DysfunctionJournal of Cerebral Blood Flow & Metabolism, 1999
- The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.Journal of Clinical Investigation, 1991